Luye Pharmaceutical (02186) fell nearly 5% in the afternoon. As of press release, it was down 4.58% to HK$2.71, with a turnover of HK$28.295,800.
The Zhitong Finance App learned that Luye Pharmaceutical (02186) fell nearly 5% in the afternoon. As of press release, it was down 4.58% to HK$2.71, with a turnover of HK$28.295,800.
According to the news, Luye Pharmaceutical announced annual results. The group received revenue of 6.143 billion yuan during the period, an increase of 2.7% over the previous year; profit attributable to shareholders was 533 million yuan, a decrease of 11.94% over the previous year; and the basic profit per share was 14.29 points, with no dividends.
According to the announcement, during the reporting period, the Group's sales revenue for oncology products decreased to 2.122 billion yuan, a year-on-year decrease of about 184 million yuan or 8.0%; sales revenue of cardiovascular products increased to 1,687 million yuan, an increase of about 152 million yuan or 9.9%; sales revenue of digestive and metabolic products decreased to 450 million yuan, a year-on-year decrease of about 182 million yuan or 28.8%; and revenue from central nervous system products increased to 1,695 million yuan, an increase of about 372 million yuan or 28.1% year on year.